News Column

Hangzhou Tianmushan Takes Stake in Hunan Shangkang

May 8, 2014

HANGZHOU, May 8, SinoCast -- Hangzhou Tianmushan Pharmaceutical Enterprise Co., Ltd. (SHSE: 600671) revealed a letter of intent inked with Hunan Shangkang Pharmaceutical E-commerce Ltd. for important restructuring by controlling shareholder during its trading suspension, planning to purchase equity in the latter through private placement and cash payment as well as finance money for following production.

Controlling shareholder planned to invite Haitong Securities Co., Ltd. (SHSE: 600837, SEHK: 6837) as exclusive financial advisor.

Trading suspension of Hangzhou Tianmushan started from April 29, 2014.

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Sinocast Health Care & Medicine Beat (China)

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters